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doi:10.1016/j.ejvs.2008.12.009Abstract Objectives: Inflammatory and other processes mediating impairment of endothelial
function, where there are increased levels of C-reactive protein (CRP) and plasma nitrites,
have a part to play in the early stages of peripheral arterial disease (PAD). Our objective
was to analyse the effect of statins on the plasma nitrite and CRP levels in PAD.
Material and methods: A prospective study of 30 patients with PAD Fontaine stage II, with no
prior treatment with statins, determined high sensitivity (hs)-CRP and lipid profile in the
patients. Plasma nitrite levels were determined by colourimetric assay based on the Griess
reaction, at baseline and after 1 month of treatment with atorvastatin 40 mg day1.
Results: A significant reduction in plasma nitrite levels was detected after the treatment with
statins (11.88 7.8 mM vs. 5.7 1.8 mM, pZ 0.0001). There was also a significant reduction in
hs-CRP levels (13.58 24.00 vs. 3.93 3.19, pZ 0.02).
When the patients were stratified according to claudication stage, a significant reduction in
nitrite levels was obtained, both in patients with PAD Fontaine stage IIA (9.5  3.3 mM vs.
5.3 1.7 mM, pZ 0.0001) and in stage IIB (16.6 11.6 mM vs. 6.7 1.8 mM, pZ 0.032).
Conclusions: Treatment with statins lowers plasma nitrite and CRP levels in patients with PAD.
Our data support the effects of statins in vivo that have been demonstrated on the endothe-
lium ex vivo, suggesting a beneficial effect by acting on the initial processes that trigger the
disease, reducing oxidative stress (increase in the bioavailability of nitric oxide as peroxyni-
trite levels decrease) and curtailing the inflammatory processes which perpetuate the disease.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Haro Miralles, C/Playa de
Monte, Madrid, Spain. Tel.:
hoo.es (J. De Haro Miralles).
ty for Vascular Surgery. PublisheEndothelial dysfunction is considered to be an early marker
for atherosclerosis, preceding evidence of atherosclerotic
plaques on angiography or ultrasound scan. Endothelial
dysfunction has been attributed to a deterioration in nitricd by Elsevier Ltd. All rights reserved.
444 E. Martı´nez Aguilar et al.oxide (NO) bioactivity and an increase in the formation of
oxygen free radicals.1 NO has several antiatherosclerotic
effects, such as inhibition of monocyte migration, inhibition
of smooth muscle cell proliferation and inhibition of
platelet aggregation.2e4 In patients with peripheral arterial
disease (PAD), an increase in plasma nitrite levels has been
observed; this increase can be detected from the first
stages of the disease, but has no correlation with the
severity.5
C-reactive protein (CRP) is a systemic inflammation
marker, and its concentration has been associated with
the future development of atherothrombotic events, both
in patients with known cardiovascular disease and in
apparently healthy subjects.6 A linear association has
been demonstrated between the clinical severity of PAD
and an increase in high sensitivity (hs)-CRP plasma levels.7
We know that CRP has a role in the modulation of the
harmful effect of oxidised low-density lipoprotein (LDL) on
endothelial function, contributing to oxidative stress and
the subsequent production of free radicals (superoxide
anion). These free radicals are capable of directly inac-
tivating the NO, producing peroxynitrite e which is
a cytotoxic, proinflammatory and potent oxidant e and
may contribute to damage and endothelial dysfunction
and to oxidation of the lipoproteins in atherosclerotic
lesions.8,9
In studies in vitro with endothelial cell cultures and in
studies with animals fed diets rich in cholesterol, it has
been seen that statins are capable of increasing endothelial
nitrous oxide synthase (eNOS) expression, reducing the NO/
peroxynitrite ratio (by preventing the NOS from ‘uncou-
pling’ and subsequently acting as nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase), increasing levels
of tetrahydrobiopterin (BH4) in the endothelial cells, pre-
venting the formation of atherosclerotic plaques and
reducing CRP levels.10e14
Our objective was to analyse the effect produced by
treatment with statins on plasma levels of nitrites and CRP
in patients with Fontaine stage II PAD.Material and Methods
A prospective study was carried out which selected 30
patients with Fontaine stage II PAD, confirmed by haemo-
dynamic study (Doppler) and treadmill stress tests, with no
previous re-vascularisation and no treatment with statins or
contraindications for their use. All patients received
treatment with atorvastatin 40 mg daily for 1 month.
Cardiovascular risk factors, treatment and general
condition were recorded on inclusion and after 1 month of
treatment with statins, and ankleebrachial index (ABI)
were measured at rest as per the standard technique in
the dorsalis pedis and posterior tibial arteries of both
lower limbs.15 Blood tests were performed at baseline and
after treatment with statins, including basic clinical
chemistry (blood sugar, renal function, electrolytes, etc.)
and lipid profile. Patients were considered to be hyper-
tensive if they presented with systolic blood pressure
greater than 140 mmHg and/or diastolic pressure greater
than 90 mmHg and/or were on antihypertensive treatment
for at least 1 year prior to inclusion in the study.16 Patientswith plasma total cholesterol greater than 6.5 mmol l1,
LDL cholesterol greater than 3.2 mmol l1 or triglycerides
greater than 2.25 mmol l1, or those on lipid-lowering
treatment were considered to have dyslipidaemia.17
Patients were considered diabetic if they presented with
baseline blood sugar greater than 120 g dl1 or if they
required treatment with hypoglycaemics.18 Chronic renal
failure was defined as serum creatinine greater than
1.5 mg dl1.19
For the determination of plasma nitrite levels, the
subjects came to the study having fasted for at least 12 h
and without having taken their usual medication during
that period. Blood was drawn from an antecubital vein and
centrifuged for 10 min at 800g, with plasma then being
stored at 4 C. Plasma nitrite concentrations were
determined by colourimetric assay based on the Griess
reaction.20 This is a chemical reaction which uses sulfa-
nilamide and N-(1-naphthyl)ethylenediamine dihydro-
chloride (NED) under acidic conditions (phosphoric acid).
The system can detect NO2
 in a variety of biological and
experimental fluids, the limit of detection being 2.5 mM
(125 pmol). Each sample was analysed in triplicate, taking
the mean of the three determinations. The blood tests
were repeated in a control group of 10 patients to assess
the reproducibility of the test, the coefficient of variation
being less than 5%.
A venous blood sample was also taken to determine
plasma concentrations of CRP using an automated high-
sensitivity immunoassay (Roche Diagnostics), with a lower
limit of detection of 0.2 mg l1 and a coefficient of varia-
tion of 4.2% in 4 mg l1 and 6.3% in 1 mg l1.21
Statistical analysis
The sample size necessary for the detection of significant
differences was calculated on the basis of previous studies
which analysed the NO plasma levels and hs-CRP.5,7 A Stu-
dent’s t-test for paired samples was used for these vari-
ables with normal distribution. The analysis of normality
was carried out using the KolmogoroveSmirnov and Sha-
piroeWilk tests. Spearman’s rho test was used for the
correlation between variables.
The data are expressed as mean standard deviation
and the categoricals as percentages. The hs-CRP data are
expressed as median 25th and 75th percentiles. Statis-
tical significance was assumed for p< 0.05.
Results
Thirty patients with Fontaine stage II PAD were recruited.
The patient demographics and current treatment are
described in Table 1. No adverse reactions to the treatment
with statins were recorded.
A significant reduction in plasma levels of total choles-
terol, LDL cholesterol, total cholesterol/high-density lipo-
protein (HDL) cholesterol ratio and total triglycerides was
observed (Table 2).
After 1 month of treatment with statins, a significant
reduction in plasma nitrite levels was detected in these
patients (11.88 7.8 mM vs. 5.7 1.8 mM, pZ 0.0001)
(Fig. 1).
Table 1 Demographic data and treatment
Patients
n %
Age (years) 71.37 10.81 (52e94)
Gender
Male 26 86.7%
Ischaemia stage:
IIA 20 66.7%
IIB 10 33.3%
Hypertension 22 73.3%
DM 12 40%
Smoking
Current 12 40%
Ex-smoker 10 33.3%
AMI 4 13.3%
Dyslipidaemia 8 26.7%
CVA 2 6.7%
COPD 9 18%
AGGREG. inhibitor 26 86.7%
ACE inhibitors 14 46.7%
ARA-II 4 13.3%
B-BLOCKER 4 13.3%
Nitrites 2 6.7%
CA-Antagonists 6 20%
DM, diabetes mellitus; AMI, acute myocardial infarct; CVA,
Cerebrovascular accident; COPD, chronic obstructive pulmo-
nary disease; AGGREG, aggregation.
Figure 1 Comparison of plasma nitrite levels (mM) at base-
line and post-treatment with statins. *p< 0.05.
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statistically significant reduction after 1 month of treat-
ment with atorvastatin (13.58 24.00 vs. 3.93 3.19,
pZ 0.02) (Fig. 2).
When we adjusted the data at baseline to Fontaine stage
as an adjustment variable in order to eliminate a potential
confounder (as earlier stage of the disease), we did not find
that the stages of claudication were independent of plasma
nitrite levels (decreased significantly both in patients with
stage IIA ischaemia and in stage IIB; pZ 0.78). However, it
was independent of the hs-CRP levels (hs-CRP levels
decreased significantly in the patients with stage IIATable 2 Initial lipid-profile values and values after 1
month of treatment with statins
Mean SD P
Total CHOL baseline 5.39 1.28 mmol l1 0.0001
Total CHOL after treatment 3.79 0.15 mmol l1
LDL CHOL baseline 3.38 1.07 mmol l1 0.0001
LDL CHOL after treatment 1.85 0.60 mmol l1
HDL CHOL baseline 1.34 0.28 mmol l1 0.12
HDL CHOL after treatment 1.4 0.39 mmol l1
CHOL/HDL baseline 4.02 0.86 0.0001
CHOL/HDL after treatment 2.76 0.63
TGC baseline 1.30 0.53 mmol l1 0.024
TGC after treatment 1.07 0.43 mmol l1
TGC/HDL baseline 2.34 1.35 0.113
TGC/HDL after treatment 1.99 1.21ischaemia, but not in those with PAD Fontaine stage IIB,
pZ 0.01).
Discussion
High levels of LDL and oxidative stress lead to endothelial
dysfunction. The result is a drop in the bioavailability of
endothelial NO, a reduction in the effective lumen of the
vessel and an increase in sensitivity to acetylcholine-
induced vasoconstriction. The levels of oxidised LDL
(ox-LDL) are increased in patients with coronary artery
disease or diabetes and are an independent predictive
factor for future cardiac events in these patients.22 Ox-LDLs
reduce the expression of eNOS proteins and the bioavail-
able NO concentration, while at the same time producing
an increase in the release of peroxynitrite, reflecting an
increase in oxidative stress.23
It could be assumed that the ability of statins to reverse
these abnormalities is simply the result of a reduction in
LDL levels, since an increase in these levels can in itself
cause endothelial dysfunction.24 However, it has been
demonstrated that the beneficial effects of statins on theFigure 2 Comparison of hs-CRP levels (mg l1) at baseline
and post-treatment with statins. *p< 0.05.
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Both properties of statins promote an improvement in
endothelial function and in the production of NO.26,27
The beneficial effects on endothelial function produced
by the statins have been demonstrated in studies with
endothelial cell cultures and in animal models subjected to
diets rich in cholesterol. The statins increase the
bioavailability of NO and reduce levels of peroxynitrite e
the main component of oxidative stress e increasing the
NOeperoxynitrite ratio, crucial in maintaining endothelial
function. This beneficial effect on the function of the
enzyme eNOS is produced on both normal endothelium and
extensively dysfunctional endothelium.10 The effect on the
release of NO in the endothelial cells produced by the
statins is the result of an increase in eNOS expression and
reduced eNOS ‘uncoupling’. When BH4 levels are low and/
or the production of superoxide anion increases, NOS
‘uncouples’ and behaves like an NADPH oxidase, increasing
the production of superoxide anion and hydrogen peroxide
more than that of NO, whereby the net balance is
a reduction in NO activity.9,28 The statins are capable of
reducing superoxide anion levels through the inhibition of
NADPH oxidase.29 They are also capable of increasing GTP
cyclohydrolase I (GTPCH) e the first and rate-limiting
enzyme in BH4 synthesis in the endothelial cells. The sta-
tins are thus able to increase levels of BH4, an essential
cofactor involved in the functioning of eNOS, both via
GTPCH and by preventing the oxidation of BH4 to radical
BH3, as a result of reducing the levels of peroxynitrites.
This then prevents the ‘uncoupling’ of the NOS, thus
breaking the vascular oxidative stress cycle.10,11,30 In
previous studies, increased plasma nitrite levels have been
observed in patients with PAD from very early stages.5 In
our study, we corroborated the action of statins on the
reduction in plasma nitrite levels and the subsequent
improvement in the bioavailability of NO in patients with
PAD, finding a significant reduction in plasma nitrite levels
in these patients.
Raised CRP levels seem to be an independent predictive
factor for cardiovascular events in patients with PAD,31
and there is a linear correlation between the increase in
plasma CRP levels and the severity of the disease in these
patients.7 This finding strongly suggests the existence of
an inflammatory substrate in the aetiopathogenesis of
PAD. We know that CRP has a role in modulating the
harmful effect of ox-LDL on endothelial function,
contributing to oxidative stress and the subsequent
production of free radicals (superoxide anion) as a result
of being able to increase NADPH oxidase expression.32
These free radicals are capable of destroying the BH4
cofactor and directly inactivating NO, producing perox-
ynitrite and thereby contributing to the damage and to
endothelial dysfunction and to oxidation of the lipopro-
teins in the atherosclerotic lesions.8,9 CRP can also
directly inhibit the activity of the enzyme GTPCH,
reducing BH4 levels and leading to the ‘uncoupling’ of
eNOS and a decrease in the bioavailability of NO.33 An
increase in peroxynitrite levels has been observed when
iNOS is expressed.9,34 Thus, CRP stimulates the production
of NO by NOS, increasing its oxidation and nitrosylation
and reducing BH4 levels, promoting the formation of free
radicals, which, in turn, inactivate the NO produced anddestroy BH4, resulting in endothelial dysfunction. In fact,
it has been demonstrated in in vitro studies that CRP is
capable of stimulating the production of NO, independent
iNOS stimulation.34 A reduction in CRP levels has been
described in patients with atherosclerosis treated with
statins e a reduction which is independent of baseline
lipid levels.14 In our study, we also observed a significant
reduction in hs-CRP levels in patients with PAD after 1
month of treatment with statins. The fact that statistical
significance was not found in the reduction in hs-CRP
levels in patients with Fontaine stage IIB PAD may be due
to the small sample size as, being a sub-analysis of the
initial group, it is likely that there were too few patients
for statistical significance to be achieved.
The REACH Registry35 is the largest worldwide registry
designed to obtain information on cardiovascular risk-
factor control and preventive treatment in a population
who have, or are at high risk of having, symptoms of
atherothrombosis. This is a registry of consecutive patients
who have risk factors only (RFO) for atherothrombosis or
who have symptomatic vascular disease (VD): coronary
heart disease (CHD) and/or cerebrovascular disease (CVD)
and/or peripheral artery disease (PAD). Statin therapy rate
was 65.2% vs. 65.6% (no significant difference). Significant
differences were found among the CHD, CVD and PAD
groups as regards statin therapy rate (78.2%, 51.9% and
57.8%, respectively; p< 0.005). The results of our work
suggest that patients with claudication due to PAD might
benefit from statin therapy independent from serum lipid
levels due to the effect of atorvastatin in reducing serum
nitrite levels and levels of CRP, because current evidence
supports that reduction in nitrite levels is associated with
increased bioavailability of NO and because reduction of
CRP correlates with reduced systemic inflammatory
activity.
Our study has potential limitations that should be
acknowledged. One is the fact that nitrite levels are influ-
enced by many exogenous and endogenous factors,
including dietary nitrate uptake, inhalation of atmospheric
gaseous nitrogen oxides, salivary formation and renal
function. Even if we cannot exclude that these factors may
have influenced nitrite levels, our data are in accordance
with previous studies. Although it could seem that the fact
that we assessed only the plasma nitrite levels and no other
nitrates is a limitation of the study, we know that other-
wise, in physiological conditions, more than 70e90% of
plasma nitrites derive from the activity of the eNOS.36
Another limitation is the small size of patient samples in the
analysis of subgroups, and this confers a low statistical
power to the results of this sub-analysis.
Treatment with statins reduces plasma nitrite and CRP
levels in patients with PAD. Our data validate in vivo the
effects of statins demonstrated ex vivo on the endothe-
lium, which produce a beneficial effect by acting on the
initial processes which trigger the disease, reducing
oxidative stress (increase in bioavailability of NO on
decreasing peroxynitrites levels) and curtailing the inflam-
matory processes which perpetuate the disease.
Conflict of Interest
The authors have no conflict of interest to declare.
Treatment Perspectives on the Origin of Peripheral Arterial Disease 447Acknowledgements
We thank Anna Bergos at the Clinical Research Department
of SanofieAventis (Barcelona, Spain) for her help in the
preparation of the English version of this article.
References
1 Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as
a signaling molecule in the vascular system: an overview.
J Cardiovasc Pharmacol 1999;34:879e86.
2 Harrison DG. Cellular and molecular mechanism of endothelial
cell dysfunction. J Clin Invest 1997;100:2153e7.
3 Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. Increased
nitric oxide bioavailability in endothelial cells contributes to the
pleiotropic effect of cerivastatin. Circulation 2002;105:933e8.
4 Kalinowski L, Malinski T. Endothelial NADH/NADPH-dependent
enzymatic sources of superoxide production: relationship to
endothelial dysfunction. Acta Biochim Pol 2004;51:459e69.
5 De Haro J, Martı´nez-Aguilar E, Flo´rez A, Varela C, March JR,
Acı´n F. Nitric oxide: the hinge between endothelial dysfunction
and inflammation in peripheral arterial occlusive disease
patients. Interact CardioVasc Thorac Surg 2008;7 (Suppl. 1):S1.
6 Pepys MB, Hirschfield GM. C-reactive protein: a critical update.
J Clin Invest 2003;111:1805e12.
7 De Haro J, Acin F, Lopez-Quintana A, Medina FJ, Martinez-
Aguilar E, Florez A, et al. Direct association between C-reactive
protein serum levels and endothelial dysfunction in patients with
claudication. Eur J Vasc Endovasc Surg 2008;35(4):480e6.
8 Barbato JE, Tzeng E. Nitric oxide and arterial disease. J Vasc
Surg 2004;40:187e93.
9 Miyoshi T, Li Y, Shih DM, Wang X, Laubach VE, Matsumoto AH,
et al. Deficiency of inducible NO synthase reduces advanced but
not early atherosclerosis in apolipoprotein E-deficient mice.
Life Sci 2006;79:525e31.
10 Heeba G, Hassan MKA, Khalifa M, Malinski T. Adverse balance of
nitric oxide/peroxinitrite in thedysfunctional endotheliumcanbe
reversed by statins. J Cardiovasc Pharmacol 2007;50:391e8.
11 Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMG-CoA
reductase inhibitor increases GTP cyclohydrolase I mRNA and
tetrahydrobiopterin in vascular endothelial cells. Arterioscler
Thromb Vasc Biol 2003;23:176e82.
12 Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endo-
thelial nitric oxide synthase by HMG CoA reductase inhibitors.
Circulation 1998;97:1129e35.
13 Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H,
Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an
HMG-CoA reductase inhibitor, contribute to prevention of
atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001;
154:87e96.
14 Ridker P, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term
effects of pravastatin on plasma concentration of C-reactive
protein. Circulation 1999;100:230e5.
15 Newman AB, Shemanski L, Manolio TA, Cushman M,
Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of
cardiovascular disease and mortality in the Cardiovascular
Health Study. The Cardiovascular Health Study Group. Arte-
rioscler Thromb Vasc Biol 1999;19:538e45.
16 Verdecchia P, Angeli F. The seventh report of the Joint National
Committee on the prevention, detection, evaluation and
treatment of high blood pressure: the weapons are ready. Rev
Esp Cardiol 2003;56:843e7.
17 National Heart, Lung, and Blood Institute. Third report of the
national cholesterol education program (NCEP) expert panel on
detection, evaluation, and treatment of high blood cholesterol
in adults (adult treatment panel III, or ATP III). Available from:<http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.
htm> [accessed 25.02.2006].
18 Report of the expert committee on the diagnosis and classifi-
cation of diabetes mellitus. Diabetes Care 2001;24:5e20.
19 Ferrer R, Herna´ndez-Jara J. Chronic renal insufficiency. I:
Definition, clinical course stages, progression mechanisms,
etiology, and diagnostic criteria. Nefrologia 2001;21:18e20.
20 Kleinbongard P, Rassaf T, Dejam A, Kerber S, Kelm M. Griess
method for nitrite measurement of aqueous and protein con-
taining sample. Methods Enzymol 2002;359:158e68.
21 Eda S, Kaufmann J, Roos W, Pohl S. Development of a new
microparticle-enhanced turbidimetric assay for C-reactive
protein with superior features in analytical sensitivity and
dynamic range. J Clin Lab Anal 1998;12:137e44.
22 Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K,
Miyauchi K, et al. Circulating oxidized low-density lipoprotein is
an independent predictor for cardiac event in patients with
coronary artery disease. Diabetes Care 2004;27:843e4.
23 Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipo-
protein decreases the expression of endothelial nitric oxide
synthase. J Biol Chem 1995;270:319e24.
24 Dart AM, Chin-Dusting JPF. Lipids and the endothelium. Car-
diovasc Res 1999;43:308e22.
25 Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has
cholesterol-lowering independent effects on the artery wall of
atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684e91.
26 Rosenson RS, Tangney CC. Antiatherothrombotic properties of
statins. Implications for cardiovascular event reduction. JAMA
1998;279:1643e50.
27 Davignon J, Laaksonen R. Low-density lipoprotein-independent
effects of stains. Curr Opin Lipidol 1999;10:543e59.
28 Gokce N, Keaney Jr JF, Hunter LM, Watkins MT, Nedeljkovic ZS,
Menzoian JO, et al. Predictive value of noninvasively deter-
mined endothelial dysfunction for long-term cardiovascular
events in patients with peripheral vascular disease. J Am Coll
Cardiol 2003;41:1769e75.
29 Wagner AH, Kohler T, Ruckschloss, Just I, HeckerM. Improvement
of nitric oxide-dependent vasodilatation by HMG-CoA reductase
inhibitors through attenuation of endothelial superoxide anion
formation. Arterioscler Thromb Vasc Biol 2000;20:61e9.
30 Bevers LM, Braam B, Post JA, van Zonneveld AJ, Rabelink TJ,
Koomans HA, et al. Tetrahydrobiopterin, but not L-arginine,
decreases NO synthase uncoupling in cells expressing high levels
of endothelial NO synthase. Hypertension 2006;47:87e94.
31 Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A,
Schiano V, et al. Endothelial dysfunction in peripheral arterial
disease is related to increase in plasma markers of inflammation
and severity of peripheral circulatory impairment but not to
classic risk factors and atherosclerosis burden. J Vasc Surg 2003;
38:374e9.
32 Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T,
et al. Interaction of oxidative stress and inflammatory response
in coronary plaque instability: important role of CRP. Arte-
rioscler Thromb Vasc Biol 2003;23:1398e404.
33 Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein
decreases endothelial nitric oxide synthase activity via uncou-
pling. J Mol Cell Cardiol 2007;43:780e91.
34 Clapp BR, Hirschfield GM, Storry C, Gallimore JR, Stidwill RP,
Singer M, et al. Inflammation and endothelial function. Direct
vascular effects of human C-reactive protein on nitric oxide
bioavailability. Circulation 2005;111:1530e6.
35 Sua´rez C, Cairols M, Castillo J, Esmatjes E, Sala J, Llobet X,
et al. In behalf of investigators at REACH Registry Spain. Risk
factor control and treatment of atherothrombosis. Spain REACH
Registry. Med Clin (Barc) 2007;129(12):446e50.
36 Kleinbongard P, DejamA, Lauer T, Rassaf T, Schindler A, PickerO.
Plasma nitrite reflects constitutive nitric oxide synthase activity
in mammals. Free Radic Biol Med 2003;35:1551e9.
